Terns Announces Pricing of Upsized $650 Million Public Offering
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Clinical Trial
Terns Announces Pricing of Upsized $650 Million Public Offering
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...
Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")...
Campo Indictment Exposes DEA Rotted From Within – While Medical Cannabis Research and Patients Wait Seven Years
A Federal Indictment That Reads Like a Narco-State ThrillerDEA corruption reaches new levels with the Campo indictment, even as the...
Qualia Life Sciences, Award-Winning Supplement Brand, Celebrates Its 10th Year Anniversary
With Human Studies On Every Formula, Qualia's Industry-Leading Research Standards Are Fueling Innovation and Rapid GrowthCARLSBAD, Calif., Dec. 9, 2025...
Sibel Health Awarded a $500,000 Drug Development Tools Research Grant by the FDA for a Novel AI-Enabled Wearable Sensor for Scratch Monitoring
CHICAGO, Dec. 9, 2025 /PRNewswire/ -- Sibel Health, a leader in wearable biosensing and digital health, today announced that it...
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
BOSTON, Dec. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Deep Origin on a 4.5-year project...
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting...
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire /...
Novo Nordisk has completed its acquisition of Akero Therapeutics
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq:...
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models,...
The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered “virtual hearts”
New CARDIOVERSE project combines AI, stem cells, and genetic variation to predict drug safety before human trialsBAR HARBOR, Maine, Dec....
SubjectWell Unveils New Science-Driven Framework to Transform Protocol Design, Recruitment, Engagement, and Retention
AUSTIN, Texas, Dec. 8, 2025 /PRNewswire/ -- SubjectWell, the largest global patient experience platform for clinical trials, today announced a...
Inductive Bio Announces an Up To $21M Award to Develop AI Drug Toxicity Models that Improve Drug Safety Assessment with Leading Academic and Biopharmaceutical Organizations
Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve...
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company...
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in...
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
Ra’anana, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing...
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was...